Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis Patients
- Sponsor
- Medical University of Vienna
- Study ID
- NCT00822783
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- Omalizumab — DRUG
- Placebo — DRUG
Study Details
Elevated levels of immunoglobuline E in blood are said to promote the occurence of atopic dermatitis; in fact, many patients with atopic dermatitis have high IgE levels. This study tried to explore whether the depletion of IgE from blood and skin might result in a change of immunological parameters and might alter the clinical course of the disease.
Key Dates
- Start date
- Oct 31, 2001
- Status verified
- Jan 2009
- Completion
- Apr 30, 2003
Arms
- Active Comparator: Omalizumab
- Placebo Comparator: Placebo
Related Studies
- Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis ResearchRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Studies of Skin Microbes in Healthy People and in People With Skin ConditionsRecruiting · National Human Genome Research Institute (NHGRI) · Bethesda, Maryland
- Natural History and Genetics of Food Allergy and Related ConditionsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)Recruiting · Regeneron Pharmaceuticals · Boston, Massachusetts